On September 29, Metsera (MTSR.US), which has been acquired by Pfizer (PFE.US), announced positive results from two Phase IIb weight loss studies (VESPER-1 and VESPER-13) for MET-097i. MET-097i is a first-in-class, fully biased, ultra-long-acting GLP-1 receptor agonist (GLP-1-RA) with the potential for once-monthly dosing. Metsera believes that MET-097i can match or exceed the performance of 15mg tirzepatide at steady state and plans to initiate Phase III clinical trials before the end of the year.